ArticleFrontiers in oncology2025
Fusion of contrast-enhanced magnetic resonance neurography and T1-weighted imaging improves simultaneous nerve-tumor visualization in head and neck lesions.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the application value of integrating contrast-enhanced magnetic resonance neurography (CE-MRN) with contrast-enhanced T1-weighted imaging (CE-T1WI) to improve the simultaneous imaging of nerves and tumors in the head and neck. Materials and methods: A retrospective study of 31 patients (14 neurogenic, 17 non-neurogenic) with pathologically confirmed peripheral nerve tumors (2017-2024) was conducted. All underwent 3.0 T MRI, assessed by two blinded radiologists. Tumor involvement patterns, enhancement features, MRI signs, and normalized nerve signal intensity were analyzed. Diagnostic confidence and lesion conspicuity were compared across CE-MRN, CE-T1WI, and fusion images. Statistical analysis included Mann-Whitney U test and interobserver agreement (Kappa/ICC). Results: Interobserver agreement was moderate to excellent (Kappa/ICC: 0.47-0.93). Focal involvement dominated in neurogenic tumors (92.9% vs. 52.9% diffuse in non-neurogenic, p=0.002). Traditional MRI signs: "dumbbell sign" was more frequent in neurogenic tumors (78.6% vs. 11.8%, p<0.001), while "effacement of fat plane" was common in non-neurogenic (70.6% vs. 0%, p<0.001). Novel CE-MRN signs: "enhanced target sign" (28.6% vs. 0%, p=0.032) and "nerve tail sign" (57.1% vs. 11.8%, p=0.018) were neurogenic markers, whereas "nerve effacing sign" was non-neurogenic (76.5% vs. 35.7%, p=0.033). Affected nerves showed higher signal intensity than contralateral nerves (p<0.05). Fusion images matched CE-MRN in diagnostic confidence and surpassed CE-T1WI in conspicuity (p<0.001). Conclusion: Image fusion technology addressed the limitations of CE-MRN in lesion visualization, thereby enhancing diagnostic confidence. The novel signs and nerve signal alterations observed in CE-MRN provide visual evidence for the accurate diagnosis and differentiation of head and neck tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.